PLK4:中心球重复的主调节器及其治疗潜力
Muhammad Hamzah1, Franz Meitinger1, Midori Ohta1
1Okinawa Institute of Science and Technology Graduate University, Okinawa, Japan.
Cytoskeleton (Hoboken, N.J.)
|April 21, 2025
概括
波罗类激酶4 (PLK4) 抑制剂会产生中枢细胞,触发p53. 具有TRIM37放大功能的癌症表现出p53独立的脆弱性,使PLK4成为有前途的癌症治疗标.
科学领域:
- 细胞生物学 细胞生物学
- 分子瘤学分子瘤学
- 遗传学 是一个遗传学.
背景情况:
- 中心体和基于微管的螺旋组件对于细胞分裂期间精确的染色体分离至关重要.
- 波罗样类激酶4 (PLK4) 调节中心重复,确保每个细胞有两个中心;其功能障碍通过中心放大导致遗传障碍或癌症.
- PLK4 抑制剂诱导中枢细胞,导致长时间的线粒分裂和p53激活,这是一个瘤抑制机制.
研究的目的:
- 审查了解中心重复和中心体细胞分裂的最新进展.
- 探索TRIM37放大在PLK4抑制后的p53-独立漏洞中的作用.
- 将PLK4定位为特定癌症类型的潜在治疗标.
主要方法:
- 关于PLK4,中心重复和癌症治疗的最新研究的文献综述.
- 分析p53独立机制的癌症与染色体增益或17q23的放大 (TRIM37).
- 专注于表现出TRIM37放大的神经母细胞瘤和乳腺癌模型.
主要成果:
- 抑制PLK4导致中枢细胞的形成,并触发了p53依赖的线粒细胞监测.
- 致使p53无能化的突变在癌症中很常见,从而损害了这种监控机制.
- 具有17q23放大 (TRIM37) 的癌症对PLK4抑制具有p53-独立的脆弱性,特别是在神经母细胞瘤和乳腺癌中.
结论:
- PLK4是中心细胞复制的主调节者,其抑制是潜在的抗癌策略.
- 在某些癌症中,TRIM37放大给PLK4抑制赋予了p53独立的脆弱性.
- 向PLK4代表了新型癌症疗法的一个有希望的途径,特别是在TRIM37增强瘤中.
关键词:
癌症 癌症 癌症 癌症 癌症中心运动 (Centrioles) 是一个中心运动.中心体的中心体是什么这是一种激酶抑制剂 (kinase inhibitor).发生线粒分裂 (mitosis).周心状物质是周心状物质.治疗药物 治疗药物更多相关视频
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.3K
09:51Generation of Stable Human Cell Lines with Tetracycline-inducible Tet-on shRNA or cDNA Expression
Published on: March 5, 2013
35.2K
相关概念视频
Centrosome Duplication
3.8K
The primary microtubule organizing center (MTOC) in animal cells is the centrosome. A centrosome has two cylindrical centrioles at its core. Each centriole consists of nine sets of three microtubules held together by proteins. The centrioles are positioned at right angles to each other and surrounded by a shapeless protein cloud called the pericentriolar matrix, or pericentriolar material (PCM).
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
3.8K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cytoskeletal Linker Proteins - Plakins
2.2K
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
2.2K
M-Cdk Drives Transition Into Mitosis
5.4K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K
Negative Regulator Molecules
35.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.0K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
